Navigation Links
Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
Date:10/26/2007

Live Webcasts from San Diego on November 2nd and New York on November 5th

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that the Company will present at three upcoming investor conferences:

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

-- Richard Ghalie, M.D., Chief Medical Officer, will present at the BIOCOM

Investor Conference at 11:00 a.m. Pacific time on Friday, November 2,

2007, from the San Diego Marriott Del Mar;

-- John P. Longenecker, Ph.D., President and Chief Executive Officer, will

present at the Acumen BioFin Rodman & Renshaw Healthcare Conference at

10:35 a.m. Eastern time on Monday, November 5, 2007, from the New York

Palace Hotel; and

-- Dr. Longenecker will also present at the CIBC World Markets Healthcare

Conference at 1:20 p.m. Eastern time on Monday, November 5, 2007, from

the Waldorf-Astoria in New York.

Live webcasts of all three presentations can be accessed at http://www.favrille.com. Replays will be available approximately one hour after each presentation and archived for one month.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... PBI-Gordon Corporation is pleased to announce Dave Loecke has ... 15-year career with PBI-Gordon, Dave has served in a wide variety of roles. His ... development and launch of many of PBI-Gordon’s most successful products. , “Dave has been ...
(Date:5/26/2016)... , May 26, 2016  Agriculture nutrients are ... Des Moines, Iowa is running their nitrate ... Lake Erie and coastal regions nationwide ... to preventing this widespread issue. NECi Superior ... Upper Peninsula, developed a new, easy to use ...
(Date:5/26/2016)... ... 2016 , ... After several promising treatments in Panama using ... of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient received his ... following FDA approval of a second application for a single patient, investigational new ...
(Date:5/25/2016)... Thailand (PRWEB) , ... May 25, 2016 , ... ... participation of a Thai delegation at BIO 2016 in San Francisco. Located at ... sector will be available to answer questions and discuss the Thai biotechnology and ...
Breaking Biology Technology:
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):